When would you consider adding adjuvant PARP inhibitor in a young gBRCA mutated patient with HR+,HER2- early breast cancer?  


Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at NYU Winthrop Hospital
I will wait for Phase III randomized trials to see...
Medical Oncologist at Cancer Treatmt Center of America
NEOTALA study is open for neoadjuvant use of Taloz...
Sign in or Register to read more